eTable 1. Characteristics of Singleton Children (n=6669) by Whether Maternal Consent to Child Prescription Data Linkage Was Granted
eTable 2. Characteristics of Singletons Who Participated in the 54-Month Follow-up and Had Prescription Data Linkage Consent (n=5520) by Whether Weight and Height Were Measured at Age 54 Months
eTable 3. Characteristics of Singleton Children in the Analytic Sample (n=5128) by Whether They Were Excluded From Multivariable Analyses Due to Missing Data
eTable 4. Perinatal Factors Potentially Associated With Antibiotic Exposure by Age ≤48 Months
eTable 5. Environmental and Social Factors Potentially Associated With Antibiotic Exposure by Age ≤48 Months
eTable 6. Sex-Stratified Unadjusted Associations of Any Antibiotic Exposure by Age ≤48 Months With Body Mass at Age 48-68 Months
eTable 7. Unadjusted Associations of Exposure to Penicillins by Age ≤48 Months With Body Mass at Age 48-68 Months (n=5128)
eTable 8. Unadjusted Associations of Exposure to Macrolides, Cephalosporins and Co-trimoxazole by Age ≤48 Months With Body Mass at Age 48-68 Months
eTable 9. Sex-Stratified Multivariable Analysis of Antibiotic Exposure by Age 48 Months With Body Mass at Age 48-68 Months
Customize your JAMA Network experience by selecting one or more topics from the list below.
Chelimo C, Camargo CA, Morton SMB, Grant CC. Association of Repeated Antibiotic Exposure Up to Age 4 Years With Body Mass at Age 4.5 Years. JAMA Netw Open. 2020;3(1):e1917577. doi:10.1001/jamanetworkopen.2019.17577
Is repeated antibiotic exposure by age 48 months associated with higher body mass index (BMI) and the likelihood of overweight or obesity at age 54 months?
In this cohort study that included 5128 children, those repeatedly exposed to antibiotics had significantly higher BMI than those not exposed. As the number of antibiotic exposures increased, the adjusted mean BMI-for-age z scores and likelihood of obesity increased significantly.
As repeated antibiotic exposure is a potentially modifiable risk factor for childhood obesity, interventions designed to reduce overprescribing of antibiotics in primary care could examine whether reducing overprescribing decreases the prevalence of childhood obesity.
Antibiotic exposures in early life may affect weight by altering gut microbiota, potentially increasing the likelihood of childhood obesity.
To examine whether repeated antibiotic exposure by age 48 months is associated with higher body mass index (BMI) at age 54 months.
Design, Setting, and Participants
This research was undertaken within a prospective cohort study in New Zealand (Growing Up in New Zealand) that recruited 6853 children antenatally during 2009 to 2010. At the 54-month follow-up, 5734 of 6156 children (93%) had their weight and height measured. Community pharmacy antibiotic dispensing data were obtained from the New Zealand Pharmaceutical Collection database for children whose parents consented to external data linkage. The analytic sample comprised singletons with 54-month weight and height measurements, community antibiotic dispensing and birth weight data, gestational age greater than 27 weeks, and no congenital anomalies. Data analysis took place from 2017 to 2018.
Antibiotic exposure (yes or no), the number of dispensings, age at first exposure, and timing (age) of exposures between birth and age 48 months.
Main Outcomes and Measures
World Health Organization BMI-for-age z scores; and International Obesity Task Force overweight and obesity cutoff points that pass through adult BMI values of 25 and 30.
Of the 5128 singletons (2622 [51%] male; mean [SD] birth weight of 3527  g), 4886 (95%) had an antibiotic prescription by age 48 months and 437 (9%) had obesity at age 54 months. Adjusted mean (SE) BMI-for-age z scores increased significantly with the number of antibiotic dispensings for 4 to 6, 7 to 9, and more than 9 dispensings (unexposed, 0.87 [0.09]; 1-3 exposures, 0.92 [0.06] [P = .57]; 4-6 exposures, 1.06 [0.06] [P = .02]; 7-9 exposures, 1.06 [0.06] [P = .02]; >9 exposures, 1.08 [0.05] [P = .01]). Additionally, receiving more than 9 dispensings was associated with greater likelihood of obesity compared with no exposure (adjusted odds ratio, 2.41; 95% CI, 1.07-5.41). Children whose exposure began in the first year of life had a higher adjusted mean (SD) BMI-for-age z score than those not exposed (1.06 [0.05] vs 0.89 [0.09]; P = .03), whereas those whose exposure commenced after the first year of life did not (1.02 [0.06] vs 0.89 [0.09]; P = .10).
Conclusions and Relevance
In this study, repeated antibiotic exposure in early childhood was associated with higher mean BMI-for-age z score and an increased likelihood of obesity. Future research could examine whether interventions such as antibiotic stewardship programs, which are designed to reduce overprescribing of antibiotics, also reduce early childhood obesity.
New Zealand has the third highest prevalence of obesity among Organisation for Economic Co-operation and Development countries.1 Pediatric obesity is associated with development of cardiovascular risk factors in later life, such as type 2 diabetes, hypertension, dyslipidemia, and metabolic syndrome.2 Antibiotic exposures in early life can change the bacterial composition of the intestine (microbiome), potentially increasing the risk of childhood obesity.3 Antibiotics affect weight by altering gut microbiota, which moderates the harvesting, storage, and expenditure of energy from dietary sources.3
Several child cohort studies have reported associations of antibiotic exposure with higher body mass index (BMI),4,5 overweight,5-7 or obesity.8-10 However, previous studies addressing this issue have limitations, including parent-reported antibiotic exposure,5,6,10 parent-reported weight and height,11 lack of height data,12 use of covariates measured at the same point as BMI,7 and restricting antibiotic exposure to children with specific diagnoses.13,14 Furthermore, previous studies were not designed to incorporate antibiotic exposure during pregnancy.
The overall aim of the present analysis was to examine the association between antibiotic exposure by age 48 months and body mass at age 54 months, using a cohort that has established linkage to antibiotic prescribing data and collected reliably measured anthropometric data. Specifically, this research evaluates whether the number, timing (age), and type of antibiotic exposures are associated with a higher body mass and an increased likelihood of overweight and obesity. This work incorporates antibiotic exposure during pregnancy.
This analysis was undertaken during 2017 to 2018 within a prospective cohort study in New Zealand (the Growing Up in New Zealand study) in which 6853 children born during 2009 to 2010 were enrolled antenatally. Birth characteristics of the cohort aligned with the national birth cohort from 2007 to 2010. The Ministry of Health Northern Y Regional Ethics Committee approved the study, and enrolled parents gave written informed consent. The Data Access Committee that was established for this cohort study approved access to data sets used in this analysis. A detailed profile of the cohort is described elsewhere.15 Reporting of this analysis followed the Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) reporting guideline.
Parents completed computer-assisted personal interviews antenatally and when their children were aged approximately 9, 24, and 54 months. Of the 6156 children who participated in the 54-month follow-up, 5734 of 6156 (93%) had both weight and height measured in duplicate by trained interviewers using standard protocols and identical sets of calibrated equipment. Where duplicate measurements of height differed by more than 1 cm or weight by more than 500 g, a third measurement was taken. The study obtained community pharmacy antibiotic dispensing data from the New Zealand Pharmaceutical Collection database for the 5666 children whose parents consented to external data linkage in addition to their mothers’ antibiotic dispensing data during pregnancy. Systemic use of antibacterial agents is via prescription only in New Zealand.
Antenatal, perinatal, and 24-month follow-up questionnaires were reviewed for availability of data to assess factors that could affect body mass. To exclude children with antenatal conditions affecting growth, the International Statistical Classification of Diseases and Related Health Problems, Tenth Revision (ICD-10) codes Q00 to Q99 were used to determine the presence of congenital anomalies.
The Figure shows the exclusion procedure used to select the study sample. This included 5406 singletons with prescription data and 54-month weight and height measurements and excluded 278 singletons who met 1 or more of the following criteria: gestational age less than 28 weeks or missing data, birth weight data missing, or congenital anomalies present. This resulted in an analytic sample of 5128 children.
Two measures of body mass were derived using the child’s weight and height measurements, age when measured, and sex. We derived BMI-for-age z scores (zBMI) using World Health Organization child growth chart standards.16 Using the child’s BMI (calculated as weight in kilograms divided by height in meters squared), age, and sex, the second measure was derived using the International Obesity Task Force (IOTF) cutoff points for overweight and obesity defined to pass through adult BMI values of 25 and 30, respectively.17 The IOTF definition is less arbitrary and was developed to encourage direct comparisons of childhood obesity trends worldwide. The IOTF BMI variable categorizes children into 3 groups (normal or underweight, overweight, and obese).
Variables measuring children’s exposure to any antibiotics and to 4 types (penicillins, macrolides, cephalosporins, and co-trimoxazole) between birth and age 48 months were derived to quantify the following: any exposure (yes or no), number of dispensings, age at first exposure, and timing (age) of exposures. Maternal exposure to antibiotics during pregnancy was quantified as any exposure (yes or no) and number of dispensings between the estimated date of conception and child’s date of birth.
The unadjusted analysis of 5128 participants examined associations of measures of antibiotic exposure with continuous variables (zBMI and potential confounders) using generalized linear models and categorical variables (IOTF BMI and potential confounders) using χ2 tests. In addition, unadjusted associations between any exposure to antibiotics (yes or no) and potential confounders were examined. Continuous variables were summarized using their means and standard deviations, and categorical variables were summarized using counts and percentages. Owing to study ethical requirements, “<10” denotes categories with fewer than 10 participants.
The multivariable analysis sample comprised 4398 children with complete (nonmissing) data for factors significantly associated (P < .05) with body mass and excluded variables with missing data for at least 10% of the analytic sample (maternal relationship status, smoking in pregnancy, and self-reported prepregnancy BMI). Missing data for self-reported prepregnancy BMI were due to a higher proportion of missing values for self-reported height (9%) than weight (4%). Therefore, self-reported weight was added to the multivariable analysis and, because it had missing values for 3% of the multivariable sample (129 of 4398), the analysis commenced with multiple imputation (25 replicates) that included the following variables: log value of self-reported weight (assumed to be missing at random), any antibiotic exposure, and factors significantly associated with body mass in the unadjusted analysis.
Using the imputed data set, multivariable generalized linear models were used to assess adjusted associations between antibiotic exposure variables and zBMI (continuous outcome); results were summarized using pooled adjusted means and their standard errors. For the IOTF BMI variable (nominal outcome), multinomial logistic regression was used to determine whether antibiotic exposure was associated with increased likelihood of overweight or obesity with normal and underweight children as the comparison group; results were summarized using pooled adjusted odds ratios (aORs) and their 95% confidence intervals. Multivariable models adjusted for the child’s sex; birth weight; delivery mode; birth season; birth order; antireflux medication dispensed by age 48 months; sleep duration at age 24 months; time spent (last weekday) watching television, DVDs, or videos at age 24 months; exclusive breastfeeding duration; and dietary intake at age 24 months. The models also adjusted for maternal age, self-identified ethnicity, education, socioeconomic deprivation,18 self-reported prepregnancy weight (log scale), antibiotic exposure in pregnancy, and alcohol use in pregnancy. Statistical analyses were performed using SAS software version 9.4 (SAS Institute Inc). A 2-tailed P < .05 was considered statistically significant.
The 5128 singletons (2622 [51%] male) had a mean (SD) birth weight of 3527 (542) g. Among mothers (mean [SD] age, 30.4 [5.8] years), 3012 of 5119 (59%) had less than a bachelor’s degree, 2098 of 5116 (41%) were of non-European ethnicities, and 1289 of 5125 (25%) lived in households in the highest quintile of area-level deprivation at enrollment.
Of 6669 singletons, 5521 (83%) had maternal consent for child prescription data (Figure). Compared with singletons whose mothers provided this consent, singletons lacking consent had lower birth weight (mean [SD], 3477  g vs 3520  g) but did not differ with respect to gestational age, delivery mode, and sex (eTable 1 in the Supplement). In addition, uniparous mothers who did not provide consent for child prescription data linkage were younger (mean [SD], 28.4 [6.2] vs 30.4 [5.9] years) and disproportionally had less than a bachelor’s degree (838 [73%] vs 3258 [60%]), were of non-European ethnicities (780 [68%] vs 2259 [41%]), and lived in households in the highest quintile of area-level deprivation (435 [38%] vs 1400 [25%]).
Among singletons whose mothers provided consent for child prescription data linkage, 98% (5405 of 5520) had both weight and height measured at the 54-month follow-up (Figure). Singletons with weight and height data did not differ significantly from those without these data with respect to birth weight, gestational age, delivery mode, and maternal age, education, ethnicity, and socioeconomic deprivation (eTable 2 in the Supplement). However, singletons lacking weight and height data were disproportionally male (71 [62%] vs 2791 [52%]).
The 4398 children included in the multivariable analyses did not differ significantly from the 730 children excluded owing to incomplete data with respect to birth weight, gestational age, delivery mode, and sex (eTable 3 in the Supplement). However, the excluded group had mothers who, at childbirth, were younger (mean [SD] age, 29.0 [6.2] vs 30.6 [5.7] years) and disproportionally had less than a bachelor’s degree (504 [70%] vs 2508 [57%]), were of non-European ethnicities (443 [62%] vs 1655 [38%]), and lived in households in the highest quintile of area-level deprivation (287 [39%] vs 1002 [23%]).
Of 5128 children in the analytic sample, 4886 (95%) were exposed to antibiotics by age 48 months. Compared with the unexposed, a larger proportion of children in the exposed group were male (2523 [52%] vs 99 [41%]), had been prescribed antireflux medications by age 48 months (771 [16%] vs 17 [7%]), had breastfed for less than 3 months (1747 [37%] vs 64 [27%]), and had consumed 3 or more servings per day of soft drinks, snacks, and fast food at age 24 months (1939 [41%] vs 73 [31%]) (eTable 4 and eTable 5 in the Supplement). The exposed group had mothers who at childbirth were younger (mean [SD] age, 30.3 [5.8] vs 31.7 [5.7] years) and disproportionally had less than a bachelor’s degree (2908 [60%] vs 104 [43%]), were of non-European ethnicity (2041 [42%] vs 57 [24%]), and lived in households in the highest quintile of area-level deprivation (1252 [26%] vs 37 [15%]).
As shown in Table 1, children exposed to antibiotics had a higher zBMI (mean [SD], 0.95 [1.20] vs 0.65 [1.02]), which also increased significantly with the number of antibiotic dispensings (dose-response association). Compared with the unexposed, mean (SD) zBMI was also higher among children whose first antibiotic course was dispensed in the first year of life (1.05 [1.25] vs 0.65 [1.02]) but not for those whose exposure commenced after age 12 months (0.78 [1.09] vs 0.65 [1.02]). These associations were significant in separate analyses for boys and girls (eTable 6 in the Supplement). Of 5128 children in the analytic sample, 437 (9%) had obesity at age 54 months. A larger proportion of children with obesity (428 [98%]) were exposed to antibiotics than normal-weight or underweight children (3448 [95%]) (Table 1). Significant trends were present for the increase in proportion of children with overweight (χ2P < .001 for trend) or obesity (χ2P < .001 for trend) as the number of dispensings increased and age of first exposure decreased.
Children exposed to and with increasing dispensings for penicillins, macrolides, cephalosporins, or co-trimoxazole had higher mean zBMI compared with no type-specific exposure (eTable 7 and eTable 8 in the Supplement). Associations between age at first exposure and increased zBMI were present in children whose exposure to penicillin began at age 0 to 6 months and greater than 6 to 12 months. For macrolides, cephalosporins, and co-trimoxazole, children whose exposure began in the first year of life had a significantly higher zBMI, but this association was also apparent for exposures initiated up to age 36 months.
Several factors were associated with both a higher mean zBMI and likelihood of overweight or obesity (Table 2 and Table 3). Child factors included sex; birth weight; delivery mode; birth season; birth order; antireflux medication dispensed by age 48 months; sleep duration at age 24 months; time spent (last weekday) watching television, DVDs, or videos at age 24 months; exclusive breastfeeding duration; and dietary intake at age 24 months. Maternal factors were age, relationship status, ethnicity, education, socioeconomic deprivation, self-reported prepregnancy weight, self-reported diabetes before or during pregnancy, and alcohol use and antibiotic exposure during pregnancy.
In multivariable analyses, antibiotic exposure was associated with both measures of body mass (Table 4). Adjusted mean (SE) zBMI increased significantly with the number of antibiotic dispensings for 4 to 6, 7 to 9, and more than 9 dispensings (unexposed, 0.87 [0.09]; 1-3 exposures, 0.92 [0.06] [P = .57]; 4-6 exposures, 1.06 [0.06] [P = .02]; 7-9 exposures, 1.06 [0.06] [P = .02]; >9 exposures, 1.08 [0.05] [P = .01]). Compared with those who were unexposed, children with 4 or more antibiotic dispensings had a higher adjusted mean zBMI, and receiving more than 9 dispensings was associated with greater likelihood of obesity (aOR, 2.41; 95% CI, 1.07-5.41). In addition, the increase in zBMI associated with 2 or more antibiotic dispensings during pregnancy remained statistically significant compared with no exposure (zBMI adjusted mean [SE], 1.08 [0.07] vs 0.96 [0.05]; P = .02). Stratified by sex, girls (but not boys) with 9 or more dispensings had a significantly higher adjusted mean (SE) zBMI than those unexposed (1.00 [0.08] vs 0.74 [0.12]; P = .02), but there was no association with overweight or obesity (aOR, 1.65; 95% CI, 1.00-2.71; P = .05) (eTable 9 in the Supplement).
The multivariable analyses showed that antibiotic exposure beginning in the first year of life was associated with higher zBMI compared with no exposure (mean [SE], 1.06 [0.05] vs 0.89 [0.09]; P = .03), whereas antibiotic exposure that commenced after the first year of life was not (1.02 [0.06] vs 0.89 [0.09]; P = .10) (Table 4). Timing of exposure was not associated with overweight or obesity in the multivariable analysis.
By antibiotic type, the multivariable analysis showed that receiving more than 6 penicillin dispensings was associated with higher zBMI (mean [SE], 1.09 [0.05] vs 0.96 [0.08]; P = .04), as was receiving 2 or more co-trimoxazole dispensings (1.11 [0.06] vs 1.00 [0.05]; P = .01) compared with no type-specific exposure (Table 4). In addition, receiving 2 or more dispensings of macrolides was associated with obesity (aOR, 1.61; 95% CI, 1.18-2.21), as was receiving 2 or more dispensings of co-trimoxazole (aOR, 1.52; 95% CI, 1.13-2.04). Neither was associated with overweight. Exposure to cephalosporins was not associated with body mass in the multivariable analysis.
In this prospective cohort study that examined the association between antibiotic exposure by age 48 months and body mass at age 54 months, repeated exposure to antibiotics was associated with higher mean zBMI and greater likelihood of obesity. Antibiotic exposure during pregnancy was also associated with an increased zBMI. In addition, children whose antibiotic exposure began in the first year of life had a higher zBMI than those who were unexposed, whereas children whose antibiotic exposure commenced after the first year of life did not differ significantly from those who were unexposed. This would be expected, as children whose exposure commences earlier in life tend to have more antibiotic dispensings over time than those whose initial exposure is delayed.
To our knowledge, this is the first study to incorporate antibiotic exposure during pregnancy in examining the association between antibiotic exposures in early childhood and body mass. Antibiotic exposure in pregnancy was associated with higher BMI in children whose mothers had 2 or more antibiotic prescriptions compared with no exposure (adjusted mean zBMI difference of 0.12), but there was no association with overweight or obesity (aOR, 1.65; 95% CI, 1.00-2.71; P = .05). Previous cohort studies19,20 examining prenatal antibiotic exposure and childhood obesity did not include the children’s own antibiotic exposure. Mor et al20 reported a higher adjusted prevalence ratio for overweight and obesity in Danish children aged 7 to 16 years whose mothers had 3 or more antibiotic prescriptions during pregnancy compared with the unexposed. In a US study19 of 436 mother-child dyads, children whose mothers self-reported antibiotic use in the second and third trimesters had higher zBMI and an increased risk of obesity at 7 years. Findings from the present study suggest that antibiotic exposure both before and after birth are associated with body mass in early childhood.
Consistent with the present study, findings from cohort studies4,9 show that children whose antibiotic prescriptions are initiated during the first 6 or 12 months of life have higher BMI on average. These findings are consistent with the notion that gut microbiota are susceptible to disruptions, particularly during infancy when the founding microbiota infants acquire at birth have not developed into a stable microbial community.3 Such disruptions can occur via infant exposure to antibiotics and possibly via maternal antibiotic exposure, as infants acquire part of their early life microbiota from their mother.3
Several cohort studies4,7-9 have reported findings comparable to the present study with regard to repeated antibiotic exposure and body mass. A retrospective cohort study in the United Kingdom8 found an increasing likelihood of obesity at age 4 years with 3 or more antibiotic exposures by age 2 years. Among children attending a primary care practice network in the United States, those with 4 or more antibiotic prescriptions at age 0 to 23 months had an increased risk of obesity at age 24 to 59 months.9 In a Canadian birth cohort,7 children with antibiotic exposure in the first year of life were 1.7 and 2.6 times more likely to be overweight at ages 9 and 12 years, respectively. A population-based study4 in Finland reported higher zBMI at age 24 months and older in children exposed to antibiotics when aged younger than 24 months and a linear trend in zBMI with increasing antibiotic prescriptions.
Other cohort studies have reported either no association between antibiotic exposure and body mass or an association of unlikely clinical significance. A cohort study in the United States14 that used health care data reported a modest association of antibiotic exposure at ages younger than 2 years with zBMI and overweight or obesity prevalence at age 5 years; the authors concluded that the clinical significance of a 0.02 to 0.07 increase in BMI z-score at age 5 years is likely negligible for individual patients. However, misclassification of antibiotic exposure is possible, as the study used electronic records (as opposed to prescription dispensing or claims) only within, but not outside, participating health care networks. Misclassification of exposures and/or outcomes also potentially explains null findings in some cohort studies. For example, a study in the Netherlands11 found no association of any antibiotic exposure or type and timing of exposure with zBMI in children, but it assessed height and weight via parental report. A study in the United States12 reported no association between antibiotic exposure in the first 6 months of life and rate of weight change at ages 2 to 5 years, but the study lacked height measurements, used clinical measures of weight collected at 30 primary care practices, and did not measure antibiotics prescribed outside of the primary care network. Another US study13 concluded that there was no association between antibiotic exposure in infancy and BMI up to age 18 years even though it was restricted to those with clinical diagnoses of infections in infancy. Excluding children with antibiotic exposure because they lacked an infection diagnosis (instead of assessing exposure irrespective of the reason for it) contributes to exposure misclassification.
Some cohort studies4,9,21,22 have reported findings comparable to the present study with regard to exposure to specific antibiotic types and BMI. Differences by antibiotic type may be due to their different modes of action on bacteria. For instance, penicillins and cephalosporins target the bacterial cell wall by interrupting cell wall synthesis during cell division, macrolides target the ribosome by interfering with protein synthesis, and sulphonamides act by inhibiting folic acid synthesis.21 Bailey et al9 found a greater risk for obesity at age 24 to 59 months in children who at ages 0 to 23 months had 4 or more treatment episodes with broad-spectrum antibiotics (defined as systemic antibiotics excluding penicillin and amoxicillin), but not for narrow-spectrum antibiotics (penicillin and amoxicillin). Saari et al4 reported that boys (but not girls) with 2 or more macrolide prescriptions by age 24 months were more likely to be overweight at age 24 months or older and have higher zBMI on average. Comparably, Korpela et al22 found an association between exposure to macrolide-type antibiotics during the previous 2 years and BMI in children aged 2 to 7 years. Furthermore, intestinal microbiota in the macrolide-exposed children showed changes previously associated with increased BMI, adiposity, obesity, or metabolic diseases in children or adults.22
This study has several strengths. It used dispensed prescription data to determine children’s antibiotic exposure at the same age to allow an equal opportunity for exposure, as well as maternal exposure during pregnancy; however, the national pharmaceutical database does not include medications prescribed in hospitals. In addition, this study examined the number, timing (age), and type (penicillins, macrolides, cephalosporins, co-trimoxazole) of antibiotic exposure. The study outcome measures were based on reliably measured BMI data in a large and ethnically diverse sample and the analyses accounted for many factors associated with body mass.
This study also has some limitations. First, mothers who did not consent to prescription data linkage and whose children had incomplete data in the multivariable analysis were disproportionally of non-European ethnicities and lived in more deprived areas. As these groups have higher obesity prevalence rates in New Zealand, this limitation may have underestimated the magnitude of the association between antibiotic exposure and body mass. Second, maternal household income was unreported by 24% of enrolled mothers (1613 of 6822); hence, it was not used in the analysis. Third, maternal BMI and gestational weight gain data could not be obtained via maternal health records. Fourth, prepregnancy weight and height were collected via self-report. A study on the validity of self-reported height, weight, and BMI by the US Centers for Disease Control and Prevention23 showed a reporting bias in these data whereby women tended to underreport their weight and overreport their height, resulting in an underestimation of BMI; underreporting of weight increased as BMI and age increased.
This study found that repeated exposure to antibiotics by age 4 years was associated with significantly higher BMI and greater likelihood of obesity at age 4.5 years. In addition, repeated antibiotic exposure in pregnancy was associated with higher BMI in young children. Timing of antibiotic exposure was also associated with BMI; compared with those who were unexposed, children whose exposure began during the first year of life had higher mean zBMI , whereas those whose exposure began after the first year of life did not. The study findings suggest that repeated antibiotic exposure may be a potentially modifiable risk factor for childhood obesity. Future research could examine whether interventions that seek to reduce unnecessary prescribing of antibiotics to children in primary care (for example, clinical rules that identify children at low risk of needing antibiotics24) can also reduce the prevalence of childhood obesity.
Accepted for Publication: October 27, 2019.
Published: January 22, 2020. doi:10.1001/jamanetworkopen.2019.17577
Open Access: This is an open access article distributed under the terms of the CC-BY License. © 2020 Chelimo C et al. JAMA Network Open.
Corresponding Author: Carol Chelimo, PhD, Department of Paediatrics: Child & Youth Health, University of Auckland, Private Bag 92019, Auckland 1142, New Zealand (email@example.com).
Author Contributions: Dr Chelimo had full access to all of the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.
Concept and design: Chelimo, Morton, Grant.
Acquisition, analysis, or interpretation of data: All authors.
Drafting of the manuscript: Chelimo, Grant.
Critical revision of the manuscript for important intellectual content: All authors.
Statistical analysis: Chelimo, Grant.
Obtained funding: Chelimo, Morton, Grant.
Administrative, technical, or material support: Camargo, Morton, Grant.
Conflict of Interest Disclosures: None reported.
Funding/Support: Dr Chelimo was supported by a research fellowship from the National Heart Foundation of New Zealand (grant 1609). The Growing Up in New Zealand prospective cohort study has been funded (grants-in-aid) by the New Zealand government and Health Research Council, University of Auckland, and Auckland UniServices Limited.
Role of the Funder/Sponsor: The research objectives addressed in this article were completed within the Growing Up in New Zealand cohort study, which was established in response to the New Zealand government’s Request for Proposals in 2004 for a new longitudinal study of New Zealand children and families. Thus, the New Zealand government had a specific role in the design of the study. The conduct of the Growing Up in New Zealand study was completed by staff affiliated with the University of Auckland and Auckland UniServices Limited; they were funded by government research contracts managed by Auckland UniServices Limited. In addition, Auckland UniServices Limited provided oversight of the conduct of the Growing Up in New Zealand cohort study by ensuring that all research contract deliverables were met. However, for the research objectives addressed in this article, the funders had no role in developing the research objectives; analysis and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication.
Additional Contributions: We thank the families participating in the study. Alison Watkins, BA; Cherie Lovell; Christin Fuchs, Diploma of Teaching; Clare Leon-Brown, BA (Hons); Diana Queenin, BA; Eleanor Cooper, MA; Elizabeth Hookings, MA; Jeannie Walker, BSc, Graduate Diploma; Juanita Hall; Julie Knight, BA; Karen Costello; Krista Hodder; Lily Xu, Graduate Diploma; Lisa Fraser; Lisa Walden; Louise Were, Graduate Diploma; Lyn Hayward, MSW; Mary La Pine, MSN; Maureen Verrill, BSc, Graduate Diploma; Penny Brander, MSc; Sarah Craig, MSc (Hons); and Sue Osborne, Advanced Trade Certificate, worked as study interviewers between study enrollment and the 54-month follow-up. These individuals were employed by the University of Auckland and Auckland UniServices Limited.